- |||||||||| Victoza (liraglutide) / Novo Nordisk
Journal: Effects of antidiabetic medications on metabolic-associated fatty liver disease (Pubmed Central) - Aug 27, 2023 Gliflozins also reduce hepatic fat content and liver enzymes used as biomarkers of steatosis. However, histological data remain scarce, especially those focusing on inflammation and fibrosis, and direct comparative data between available therapies are still lacking.
- |||||||||| pioglitazone / Generic mfg.
Enrollment change, Trial withdrawal: Pioglitazone and Insulin Resistance in ADT (clinicaltrials.gov) - Aug 15, 2023 P3, N=0, Withdrawn, Additionally, treatment with pioglitazone and alpha-lipoic acid did demonstrate a greater effect than monotherapy with each medication alone. N=40 --> 0 | Recruiting --> Withdrawn
- |||||||||| Duvie (lobeglitazone) / Chong Kun Dang
Journal: Thiazolidinediones: Recent Development in Analytical Methodologies. (Pubmed Central) - Aug 4, 2023 The specified outcomes followed extensive learning, and the most recent advances in analytical methods for the identification of pioglitazone, pioglitazone HCl, rosiglitazone, rosiglitazone maleate and lobeglitazone were reviewed. Additionally, this article briefly discusses features of analytical discovery on thiazolidinediones, which will enable readers to access all discoveries in one place with precise outcomes.
- |||||||||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Trial primary completion date: Dapagliflozin Plus Pioglitazone in T1DM (clinicaltrials.gov) - Aug 4, 2023 P4, N=120, Recruiting, Additionally, this article briefly discusses features of analytical discovery on thiazolidinediones, which will enable readers to access all discoveries in one place with precise outcomes. Trial primary completion date: Jun 2023 --> Dec 2023
- |||||||||| Journal: Kinetic Barriers to Disproportionation of Salts of Weakly Basic Drugs. (Pubmed Central) - Jul 26, 2023
Additionally, we altered an established thermodynamically based modeling framework to account for kinetic effects (representing the nucleation kinetic barrier) to estimate the solid-state stability of salt formulations. In conclusion, a solution-based thermodynamic model is mechanistically appropriate to predict salt disproportionation in a solid-state formulation, when kinetic barriers are also taken into consideration.
- |||||||||| pioglitazone / Generic mfg.
Journal: Synthesis and hypoglycemic activity of quinoxaline derivatives. (Pubmed Central) - Jul 24, 2023 The results showed that compounds 5i and 6b exhibited stronger hypoglycemic effects than the lead compounds and were comparable to the positive control Pioglitazone...The alleviating cellular OS of compound 6b was better than that of 5i, and 6b was found to bind better than 5i for most of the screening targets. In summary, compound 6b is a potential lead compound with hypoglycaemic activity.3.
- |||||||||| trichostatin A (VTR-297) / Vanda, LY294002 / Eli Lilly, tanespimycin (BMS-722782) / BMS
Journal: Idiopathic Pulmonary Arterial Hypertension: Network-Based Integration of Multi-Omics Data Reveals New Molecular Signatures and Candidate Drugs. (Pubmed Central) - Jul 21, 2023 In addition, the salient gene-based drug repositioning analysis identified alvespimycin, tanespimycin, geldanamycin, LY294002, cephaeline, digoxigenin, lanatoside C, helveticoside, trichostatin A, phenoxybenzamine, genistein, pioglitazone, and rosiglitazone as potential drug candidates for IPAH. In conclusion, this study provides new molecular signatures in relation to IPAH and attendant potential drug candidates for further experimental and translational clinical research for patients with IPAH.
- |||||||||| pioglitazone / Generic mfg.
Journal: Rediscovery of pioglitazone (Pubmed Central) - Jul 6, 2023 Orv Hetil. 2023; 164(26): 1012-1019.
- |||||||||| pioglitazone / Generic mfg.
Journal: Efficacy of 3 (Pubmed Central) - Jul 3, 2023 Long-term, controlled studies are urgently needed before they can be more broadly recommended in this setting. Similar effects were observed following low-dose pioglitazone treatment (??7.5
- |||||||||| pioglitazone / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Preclinical, Journal: The Ameliorative Effect of Pioglitazone against Neuroinflammation Caused by Doxorubicin in Rats. (Pubmed Central) - Jul 2, 2023 This was evidenced by changes in IL-1?, TNF-?, and IL-6 levels and also by mRNA expression of TNF- ?, and IL-6. In conclusion, PIO treatment produced a reversal of DOX-induced memory impairment by alleviating neuronal inflammation by modulating the expression of inflammatory cytokines.
- |||||||||| pioglitazone / Generic mfg., rosiglitazone / Generic mfg.
Retrospective data, Review, Journal: Correlation between PPARG Pro12Ala Polymorphism and Therapeutic Responses to Thiazolidinediones in Patients with Type 2 Diabetes: A Meta-Analysis. (Pubmed Central) - Jun 28, 2023 This meta-analysis reveals that patients with the Ala12 variant in the PPARG Pro12Ala polymorphism are more likely to exhibit positive responses to TZD treatment in terms of HbA, FPG, and TG levels compared to those with the Pro12/Pro12 genotype. These findings suggest that genotyping the PPARG Pro12Ala in diabetic patients may be advantageous for devising personalized treatment strategies, particularly for identifying individuals who are likely to respond favorably to TZDs.
- |||||||||| simvastatin / Generic mfg., pioglitazone / Generic mfg., acetylcysteine solution / Generic mfg.
Clinical, Review, Journal: Augmentation Therapies as Treatments for Coexisting Somatic Problems in Schizophrenia-A Systematic Review. (Pubmed Central) - Jun 28, 2023 A statistically significant reduction of negative and positive symptoms of schizophrenia, measured with the PANSS scale, when using a combination of antipsychotic treatment along with aspirin, simvastatin, N-acetylcysteine, or pioglitazone was found. A combination of antipsychotic medication with aspirin, simvastatin, N-acetylcysteine, or pioglitazone seems to be effective in the reduction of symptoms of schizophrenia in adults, but long-term studies are required to confirm this effect.
- |||||||||| pioglitazone / Generic mfg.
Journal: Bacteria-derived Outer-membrane Vesicles Hitchhike Neutrophils to Enhance Ischemic Stroke Therapy. (Pubmed Central) - Jun 26, 2023 Here, we propose a strategy based on bacteria-derived outer-membrane vesicle (OMV) hitchhiking on the neutrophils for enhanced brain delivery of pioglitazone (PGZ) to treat ischemic stroke...The results showed that OMV@PGZ simultaneously inhibited the activation of NLRP3 inflammasomes and ferroptosis and reduced the reperfusion injury to exert a neuroprotective effect. Notably, the transcription factors Pou2f1 and Nrf1 of oligodendrocytes were identified for the first time to be involved in this process and promoted neural repair by single-nucleus RNA sequencing (snRNA-seq).
- |||||||||| pioglitazone / Generic mfg.
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Insulin Resistance and Androgen Deprivation Therapy (clinicaltrials.gov) - Jun 23, 2023 P2, N=0, Withdrawn, Notably, the transcription factors Pou2f1 and Nrf1 of oligodendrocytes were identified for the first time to be involved in this process and promoted neural repair by single-nucleus RNA sequencing (snRNA-seq). N=44 --> 0 | Trial completion date: Dec 2027 --> Jan 2023 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2026 --> Jan 2023
- |||||||||| pioglitazone / Generic mfg.
Journal: Encapsulation of Pioglitazone into Polymer-Nanoparticles for Potential Treatment of Atherosclerotic Diseases. (Pubmed Central) - Jun 20, 2023 In this study, we take the first step toward an anti-inflammatory, causal antiatherosclerotic therapy, using the potential of the already established drug pioglitazone, and enable it to enrich at the target site by using nanoparticles. An additional crucial feature of our nanoparticle platform is the versatile modifiability of ligands and ligand density, to achieve an optimal active targeting effect in the future.
|